Studying the Link Between Anti-factor Xa Activity and Blood Clots in Critically Ill ICU Patients

What this Trial Is About

Researchers are investigating the link between anti-factor Xa activity antiXa and venous thromboembolism VTE, which includes deep vein thrombosis and pulmonary embolism, in critically ill patients admitted to intensive care units. This observational study aims to understand how antiXa relates to symptomatic and incidental VTE, the connection between enoxaparin anticoagulation and antiXa levels, bleeding complications, and patient outcomes such as mortality, quality of life, and length of hospital stay. The study involves patients admitted to intensive care units who do not receive therapeutic doses of anticoagulants like enoxaparin. Anti-factor Xa activity calibrated for enoxaparin is measured as a diagnostic test. Participants are observed during their stay in the intensive care unit, with data collected on the occurrence of new VTE events, bleeding, blood transfusions, medication use, and patient-centered outcomes. Participants will be monitored until discharge from the intensive care unit or up to 14 days after study inclusion for new VTE events and bleeding complications. Additional follow-up at 90 days collects data on mortality, quality of life using the EQ-5D-5L tool, length of stay in hospital and intensive care, and days alive and out of hospital or intensive care. The main measurement is the number of patients developing new VTE during this period, providing insight into risks and outcomes related to antiXa activity in critically ill patients.

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients